The treatment showed no survival benefit for patients when compared with a placebo, the North Chicago biopharma said.
An independent data-monitoring committee recommended terminating the trial due to its lack of efficacy, AbbVie said.
"Small-cell lung cancer continues to be one of the most difficult-to-treat cancers where there is a significant need for transformative therapies," Margaret Foley, a physician and vice president and global head of solid-tumor development at AbbVie, said in a statement.
"We are disappointed with this outcome for the patients who suffer from this disease."
The company said it would focus its research and development on other therapies in its oncology portfolio.
AbbVie shares are up 0.32% to $66.28 Thursday.
Save 57% With Our Labor Day Sale. Join Jim Cramer's Action Alerts PLUS investment club to become a smarter investor! Click here to sign up!